Has Ari Kostadaras, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,526 in general payments to Ari Kostadaras, MD across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ari Kostadaras, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ari Kostadaras, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ari Kostadaras, MD

Nephrology · Astoria, NYNPI 1447285911

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 32.3% of the total. Reporting peaked in 2019 at $1,427 and has fallen 59.3% since, to $581 in 2025.

$4,526in general payments, 2019–2025

Across 58 payments — averaging $78.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Johnson & Johnson$899
Vifor Pharma, Inc.$479
Akebia Therapeutics Inc$320
E.r. Squibb & Sons, L.L.C.$211
Vantive US Healthcare LLC$166
plus $988 from 8 others

What the payments were for

Food & beverage$4,45598%
Education$712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	28	$1,462
Johnson & Johnson	8	$899
Vifor Pharma, Inc.	4	$479
Akebia Therapeutics Inc	5	$320
E.r. Squibb & Sons, L.L.C.	2	$211
Vantive US Healthcare LLC	2	$166
Abbott	1	$150
Ardelyx, Inc.	1	$150
Baxter Healthcare	2	$137
Medtronic	1	$125
Aurinia Pharma U.S., Inc.	1	$125
Boehringer Ingelheim	1	$125
Sanofi-aventis U.S. LLC	1	$110
Mallinckrodt Hospital Products Inc.	1	$66

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LOKELMA$894
XARELTO$491
INVOKANA$375
Veltassa$355
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
XPHOZAH 30 MG$150
Renal - PD$145
ELIQUIS$125
HawkOne$125
LUPKYNIS$125
FARXIGA$125
JARDIANCE$125
Vafseo$124
AURYXIA$124
SOLIQUA 100/33$110

How this compares

$4,526 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York →

Medicare billing

Part B allowed, 2024

$100,855

Medicare patients

102

Services billed

601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	13	$9,207
Sevelamer Carbonate	22	$1,457
Febuxostat	12	$1,109
Metoprolol Succinate	44	$580
Torsemide	30	$395
Hydralazine Hcl	18	$280
Allopurinol	29	$278
Losartan Potassium	29	$190
Levothyroxine Sodium	21	$189
Furosemide	26	$163
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide	13	$125
Amlodipine Besylate	37	$122
Finasteride	11	$109
Montelukast Sodium	11	$107
Carvedilol	11	$70

Paid to pharmacies, not to this prescriber.

Other nephrology in Astoria

Payam ShakouriPoughkeepsie$930K
Gerald AppelNew York$842K
Richard ChanNew York$514K
Bruce SpinowitzBronx$465K
Steven CocaNew York$445K
Joseph RoglieriTroy$425K
Jai RadhakrishnanNew York$369K
Savneek ChughHawthorne$325K
Gerard TepedinoManhasset$308K
Frank CortazarAlbany$289K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →